Vg Life Sciences logo

Vg Life Sciences(OTC) VGLS

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)-100%
5 Year-98%
1 Year-11%
1 Month+89%
N/A
Vg Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.892026-10-23
Vg Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.88%USD 0.812026-10-16
1 month+89.36%USD 0.472026-09-23
3 month+85.42%USD 0.482026-07-24
Year to date-55.5%USD 2.002025-12-30
1 year-11%USD 1.002025-10-23
3 year-11%USD 1.002023-10-24
5 year-98.29%USD 52.002021-10-22
Since inception-100%USD 17,767,106.842001-10-03

Vg Life Sciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$355.18K

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 5, 2025

VGLS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vg Life Sciences

SB Technology Holdings Inc. is a financial services company based in New York, primarily operating as a subsidiary of KH Feelux Co., Ltd. The company has historically engaged in research and development of pharmaceutical and medical products, although it currently does not have significant operations.

Products and Services
  • Research and development of therapeutic products
  • Diagnostic pharmaceutical solutions
  • Medical product innovations
Growth Outlook
  • Recent quarterly net income showed a significant increase to $199,728
  • Trailing twelve months (TTM) net income improved compared to previous periods
  • Potential for future growth as the company explores new opportunities
Financial Highlights
  • Quarterly revenue remains at $0, indicating a focus on cost management
  • Net income for the latest quarter was $199,728, a notable recovery
  • Operating expenses decreased from $78,595 to $66,258 over recent quarters
SB Technology Holdings Inc. presents a unique opportunity for investors interested in companies with potential for recovery and growth. The recent financial performance indicates a shift towards profitability, with a notable increase in net income in the latest quarter. Despite the lack of current revenue, the company's focus on managing operating expenses may position it favorably for future developments. Investors may find the company's historical expertise in pharmaceuticals and medical products appealing as it navigates its next steps in the market.
AI Generated • Oct 24, 2026

Industry

Biotechnology

CEO

William P. Farrand

Headquarters

New York, NY 10013, US

VGLS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$296.55K

EBITDA

-$541.09K

Operating Cash Flow

-$22.46K

Capital Expenditure

$0.00

Free Cash Flow

-$22.46K

Cash & ST Invst.

$0.00

Total Debt

$2.11M

Vg Life Sciences Performance Analysis

Vg Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Vg Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Vg Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 3.80N/A
20232023-12-31USD -3.00N/A
20242024-12-31USD -0.20-93.3%
20252025-12-31USD -0.40100.0%
Vg Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3196.7%
Q22025-06-30-150.0%
Q32025-09-30N/A
Q42025-12-31200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

1

N/A

Net Income

$199.73K

+176.3%

EBITDA

-$78.60K

+70.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$0.00

N/A

Total Debt

$2.11M

+3.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$2.11M

+3.4%

Return on Assets

0.00%

N/A

Return on Invested Capital

0.00%

N/A

Free Cash Flow

-$6.19K

-52.0%

Operating Cash Flow

-$6.19K

-52.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FONUFonU2, Inc.
$0.00+0.00%
GREHGreen Rain Energy Holdings Inc.
$0.01-2.30%
HESGHealth Sciences Group, Inc.
$0.00+0.00%
HVCWHarrison Vickers and Waterman Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About VGLS

What is the current price of Vg Life Sciences?

Vg Life Sciences is trading at N/A per share.

What is the 52-week range for Vg Life Sciences?

Over the past 52 weeks, Vg Life Sciences has traded between N/A and N/A.

How much debt does Vg Life Sciences have?

As of the most recent reporting period, Vg Life Sciences reported total debt of $516.70K.

How much cash does Vg Life Sciences have on hand?

Vg Life Sciences reported $0.00 in cash and cash equivalents in its most recent financial results.

What is Vg Life Sciences’s dividend yield?

Vg Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.